menu

TAG: GENETIKA+

Genetika+ CEO Talia Cohen Solal Brings Precision Medicine to Brain Health

BioSpace // Published October 21, 2021 | By Gail Dutton Genetika+ CEO and Co-founder Talia Cohen Solal/Courtesy Genetika+.  Depression, historically, has been treated by trial and error until a therapy with a positive and stable outcome can be identified. Genetika+ is changing that with precision, personalized testing that enables the right antidepressant to be selected for patients the first time. “We’re developing a blood test to match therapies to patients,” Talia Cohen Solal, Ph.D., CEO and co-founder of Genetika+, told BioSpace. The test doesn’t directly assay the blood, though. Instead, “We take the blood cells and use stem cell technology to cause...

READ MORE
Genetika+ – A Pioneer in Personalized Medicine for Psychiatry – Raises $10 Million in an Oversubscribed Series A

JERUSALEM AND BOSTON (PRWEB) SEPTEMBER 30, 2021 New investment underscores the company’s promise to transform precision medicine and mental health Genetika+, bringing the first personalized medicine platform for optimizing psychiatric and neurologic patient treatment, announced today that it has closed a $10 million Series A funding round led by GreyBird Ventures, a Boston-based VC focused on precision medicine. Also participating in the round are Meron Capital, Jumpspeed Ventures, Sapir Venture Partners, Howard Morgan Chairman of B Capital Group and Michael Zeisser of FMZ Ventures and former Chairman, Investments at Alibaba Group. Genetika+’s lead solution personalizes antidepressant treatment for each patient. The...

READ MORE
GreyBird Ventures

is named after the arctic tern, a bird that migrates 71,000 km annually. As they can live for 30 years, this is the lifetime equivalent of three trips to the moon and back. Not bad for a 100 gram bird. We strive to emulate its size to performance ratio as well as its global reach.

MEET THE PEOPLE

For additional information, please contact: greybird@greybirdventures.com

DISCLAIMER